


DIVERSITY

IN CLINICAL TRIALS:

WHY IT MATTERS & **HOW YOU CAN HELP**

All diseases do not affect all people equally

Many factors play a part in an individual's disease — and treatment experience, including race, gender, socioeconomic status and more.




Transgender men are more than twice as likely as cisgender men to be diagnosed with cancer²


For patients with Crohn's disease, lower income is associated with a higher risk of mortality in the hospital³



Representation is key

Despite the importance of these unique personal identifiers, many clinical trials lack diversity.





often experience stigma and prior negative experiences with health care providers that can lead to delays in seeking medical treatment, which impacts their ability to gain access to and be made aware of clinical trials⁶




A study exploring demographics of cancer clinical trial participants found that patients with an annual household income of less than \$50,000 had 32% lower odds of trial participation than those with more than \$50,000⁵



There is substantial underrepresentation of patients 65 years and older in studies of treatment for cancer⁷

Participants from underrepresented and diverse populations

are needed in clinical research for scientists to fully understand the safety and efficacy of new treatment options in such populations.



Visit researchincludesme.com to learn more about clinical trial participation and find a trial near you.

- "Cancer Stat Facts: Prostate Cancer." SEER, seer.cancer.gov/statfacts/html/prost.html. Accessed 27 July 2023.
- 2. "AACR Cancer Disparities Progress Report: The State of Cancer Health Disparities in 2022." American Association for Cancer Research (AACR), https://cancerprogressreport.aacr.org/disparities/cdpr22-contents/cdpr22-the-state-of-cancer-health-disparities-in-2022/. Accessed 27 July 2023.
- 3. Sewell, J. L., & amp; Velayos, F. S. "Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness." Inflammatory bowel diseases. March 2013 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905682/#R1919; Nguyen, G. C., Bayless, T. M., Powe, N. R., Laveist, T. A., & Brant, S. R. "Race and health insurance are predictors of hospitalized Crohn's disease patients undergoing bowel resection." *Inflammatory bowel diseases*. 13 June 2007. https://doi.org/10.1002/ibd.20200
- 4. "2020 Drug Trials Snapshots Summary Report." Drug Trials Snapshot, Feb. 2021, www.fda.gov/media/145718/download.
- 5. Price, Kyla N., et al. "Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients." Karger Publishers, 15 Dec. 2020, karger.com/drm/article/237/5/843/819999.
- 6. Price, Kyla N., Afsaneh Alavi, et al. "Gender Minority Patients in Dermatology Clinical Trials." International Journal of Women's Dermatology, 12 June 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC8060670/#b0030.
- 7. Huang, Li-Wen. "Cancer Clinical Trial Enrollment in Older vs Younger Adults." JAMA Network Open, 10 Oct. 2022, jamanetwork.com/journals/jamanetworkopen/fullarticle/2797076#:~:text=Adults%2070%20years%20or%20older,in%20NCI%2Dsponsored%20clinical%20trials.